Introduction
Targeted gene therapy has been considered to have a strong potential in cancer therapy. Like other gene therapy procedures, targeted cancer gene therapy also has to overcome many practical obstacles prior to clinical application. 1 The ideal delivery vehicle would be one that could be administered systemically and selectively targeted to tumor cells, wherever they occur in the body. 2 A great deal of progress has been made toward developing non-viral pharmaceutical formulations of genes for in vivo human therapy, particularly liposome-mediated gene transfer systems. 3, 4 Targeting of liposomal vectors to cancer cells can be achieved by modifying the liposomal surface through addition of targeting molecules, such as antibodies or antibody fragments, so that they selectively deliver their payload to tumor cells. 5 Gene delivery to a specific site by immunoliposomes represents a potentially attractive mode of gene therapy. 6 However, although immunoliposomes bind effectively and specifically to target cells, their in vivo delivery efficiency usually does not reflect in vitro results. 5, 7 This poor in vivo delivery is mainly due to enhanced uptake of these liposomes by the reticuloendothelial system (RES) as a consequence of antibody conjugation to the surface of these vehicles and their recognition by Fc-receptors of mononuclear phagocytes. 8 On the other hand, the antibody density on the liposomal surface is a major parameter governing in vivo target-specific delivery. 9 Thus, apparently efficient targeting and low RES uptake of immunoliposomes appear to be mutually exclusive. However, it has been suggested that coating of the liposomal surface with amphipathic polyethylene glycols (PEG-immunoliposomes (PILs)) can protect liposomes from RES uptake and prolong their circulation. 10 We have developed a new formulation of PILs, which can effectively deliver therapeutic genes to target cells in vivo. These immunoliposomes consist of cationic O,O 0 -dymyrisyl-N-lysyl aspartate (DMKD) 11 and anionic 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-maleimide polyethylene glycol 2000 (DSPE-PEG 2000 -Mal) for coupling of antibody Fab 0 fragments. PEG provides for prolonged circulation, while conjugation of Fab 0 fragments of humanized monoclonal antibody, HuCC49, 12 specific for LS174 T human colon adenocarcinoma cells to PEG termini induces specific targeting. Antibody Fab 0 fragments were used instead of whole antibodies to further reduce Fc receptor-mediated RES uptake. 13, 14 Conjugation via thiol residues of the Fab 0 fragments permits the retention of the antigen-binding activity of HuCC49. Also, the small PILs bearing Fab 0 fragments on the PEG termini may pass fairly readily by passive convective transport through the leaky tumor endothelium. 15 In this study, Fab 0 fragments of the humanized antitumor-associated glycoprotein-72 (TAG-72) antibody, HuCC49, were conjugated to liposomes consisting of DSPE-PEG 2000 -Mal (1 mol percent) and cationic DMKD (4 mol percent). DMKD was used to increase the encapsulation of pDNA into the immunoliposomes. Targetability of the anti-TAG-72 Fab 0 -PILs was assessed in BALB/c nude mice carrying TAG-72-positive human colon adenocarcinoma LS174 T cells. Their gene transfection capability was also determined in LS174 T cells and xenografted LS174 tumors. Finally, the anti-TAG-72 PILs-containing anticancer therapeutic genes were administered to mice carrying LS174 tumors and their efficacy was evaluated. TAG-72-mediated targeting of immunoliposomes provides a new modality of tumor-specific gene delivery, which can be clinically utilized for systemic delivery of therapeutic genes to cancer cells.
Materials and methods

Cell cultures
CHO cell line (AKA 124-0.32) 12 stably transfected with pdCMV-dhfr-AKA/Hzk encoding humanized antibody, CC49, was maintained in MEM-a (Gibco, Carlsbad, CA) supplemented with 10% dialyzed fetal bovine serum (JRH Biosciences, Lenexa, KS) and 100 mM methotrexate (Sigma, St Louis, MO). Human colon adenocarcinoma LS174 T cells (CL-188; ATCC, Manassas, VA) and human colorectal adenocarcinoma WiDr cells (CCL-218; ATCC) were cultured in minimum essential medium (Gibco) supplemented with 10% heat-inactivated bovine serum, 100 units ml À1 penicillin and 100 mg ml À1 streptomycin at 37 1C, under 5% CO 2 .
Plasmid production Plasmids pAAV-CMV-Luc, 16 pEGFP-N1 (Clontech Laboratories, Inc., Mountain View, CA), pFALGAngioK1/3, 16-18 pFLAG-Endo [16] [17] [18] and pFLAG-Sax 17 were propagated in DH5a strain of E. coli under selective LB media supplemented with ampicillin and kanamycin. The plasmids were isolated and purified with a Qiagen Endo-free plasmid megaprep kit (Qiagen, Valencia, CA). Purity was confirmed by 0.7% agarose gel electrophoresis followed by ethidium bromide staining and the DNA concentration was measured by UV absorption at 260 nm. IgG) AKA 124-0.32 cells were cultured in 2 l of SFM II media (Gibco) for 5 days and the culture media harvested by filtration through a 0.45 mm filter (Nunclon, Rochester, NY). The filtered CHO cell media was applied to a HiTrap protein-G column (Amersham Biosciences, Uppsala, Sweden) and the eluate collected in 1 ml fractions. The fractions were assayed using a detergent compatible (DC) protein assay reagent kit (Bio-Rad, Hercules, CA) and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Preparation of humanized antibody CC49 (HuCC49
Preparation of Fab 0 fragments Initially, F(ab 0 ) 2 fragments of humanized antibodies (HuCC49) were produced using an Immunopure IgG 1 F(ab 0 ) 2 preparation kit (Pierce, Rockford, IL). In brief, the HuCC49 antibodies were dialyzed using a Dialysis Cassettes (Slide-A-Lyzer 10 K, Pierce) against a 20 mM sodium acetate buffer (digestion buffer, pH 4.5). The dialyzed antibodies were concentrated with an UltraAmicon 30 K (Amicon, Beverly, CA), resuspended in 0.5 ml of digestion buffer and added to 0.25 ml of immobilized pepsin slurry (Pierce). The solution was then incubated with a serum separator tube (Pierce) for 4 h at 37 1C in a shaker water bath. The reaction solution was diluted with 4 ml binding buffer and then loaded on an Immunopure protein-A column. The eluted fractions containing F(ab 0 ) 2 were detected by a standard protein assay (Bio-Rad Protein Assay, Bio-Rad, Hercules, CA). The F(ab 0 ) 2 fragments (110 kDa) were concentrated using Centricon-50 (Amicon) and then resuspended in 1 ml phosphate-EDTA buffer (100 mM sodium phosphate, 5 mM EDTA, pH 6.0).
To cleave the disulfide bonds of the F(ab 0 ) 2 fragments, 2-mercaptoethylamine-HCl was added (0.05 M of final concentration) to the F(ab 0 ) 2 solution and the mixture incubated for 90 min at 37 1C. The resulting Fab 0 fragments were purified through a Sephadex G-25 M column (PD-10 column; Amersham Biosciences) preequilbrated with acetate-EDTA buffer (100 mM anhydrous sodium acetate, 88 mM sodium chloride and 1 mM EDTA, pH 6.5) and quantified using a standard protein assay. The Fab 0 fragments (55 kDa) were concentrated using Centricon-10 (Amicon), resuspended in acetate-EDTA buffer and kept under nitrogen atmosphere at 4 1C prior to coupling to liposomes. The purity of Fab 0 fragments was assessed by SDS-PAGE.
Detection of TAG-72 expression on LS174T
After harvesting by centrifugation, LS174 T and WiDr cells (each 1 Â 10 6 cells) were suspended in 2 ml lysis buffer (100 mM Tris-HCl, pH 7.4, 1 mM EDTA, 5 mM dithiothreitol) and lysed with a sonicator. The resulting crude cell extracts were analyzed by 6% SDS-PAGE and western blotting analysis using the HuCC49 antibody and horseradish peroxidase-conjugated goat anti-human IgG antibody (1/1000 dilution) (Santa Cruz Biotechnology Inc., Santa Cruz, CA) for detection. 20, 21 The liposome solution was then extruded through 400, 200 and 100 nm pore size polycarbonate membranes (Avanti Polar Lipids). Unencapsulated pDNA (less than 50%) was removed by exhaustive nuclease treatment. In parallel with the DNA encapsulation, HuCC49-Fab 0 fragments were covalently conjugated to maleimide groups at the termini of the DSPE-PEG 2000 -Mal chains by coincubation at 55 1C for 30 min (30 mg Fab 0 mmol À1 phospholipid). 14, 22 Unconjugated antibodies and nuclease-digested exteriorized DNA were removed from the PILs by CL-4B gel filtration chromatography (Amersham Pharmacia, Uppsala, Sweden).
DNase I protection assay DNase I (1 unit per mg of DNA; Sigma) was added to 10 ml of pAAV-CMV-Luc-encapsulating PILs prepared with varied ratios of DMKD cationic lipid and the mixtures were incubated at 37 1C for 30 min. Two microliters of 0.5 M EDTA was immediately added to stop DNase I degradation and then, 2 ml of 1% Triton X-100 was added and the mixture incubated for 20 min at room temperature to release DNA from the PILs. Finally, the reaction mixtures were run on a 0.8% agarose gel and visualized by UV illumination. The amount of pDNA encapsulated in PILs was quantified by UV spectrometry after treatment with Triton X-100. 
In vitro transfection
In vitro transfection with the anti-TAG-72 PILs was performed in 24-well plates as described previously. 23 Various formulations of PILs (10 ml), or lipoplexes of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or DMKD (6:1, N/P ratio; 10 ml) containing 1 mg pAAV-CMV-Luc were added to LS174 T or WiDr cells. The cells were transfected in the presence of 0, 10 or 60% serum for 4 h and then further incubated in fresh 10% serumcontaining media for 24 h. The transfected cells were washed twice with phosphate buffered saline (pH 7.4) and lysed using 200 ml of lysis buffer (1% Triton X-100, 1 mM dithiothreitol and 2 mM EDTA) at room temperature for 2 h. The cell lysates were centrifuged for 2 min at 12 000 g to pellet debris. Luciferase activity in the lysates was evaluated with an assay kit (Promega, Madison, WI). The relative light units were determined using a Minilumat LB9506 luminometer (Berthold, Wildbad, Germany). The protein concentrations in the lysates were measured with a DC protein assay kit. The results were expressed as relative light units of luciferase per milligram of total cellular protein.
In vivo gene transfection For in vivo gene delivery studies, nude mouse xenografts were prepared by subcutaneous injection of 2.5 Â 10 6 LS174 T cells on the lower back of 6-week-old female nude mice (BALB/cAnNCrjBgi-nu; Charles River Laboratories, Wilmington, MA). Fifteen days later, the tumor-carrying mice (n ¼ 4, average 200 mm 3 of tumor volume) were slowly injected intravenously with various formulations of anti-TAG-72 PILs (0.3 ml) encapsulating pCMV-Luc or pEGFP-N1 or DMKD/cholesterol lipoplexes of pCMV-Luc or pEGFP-N1 (6:1, N/P ratio) (50 mg DNA each mouse). To assess luciferase expression, major organs (tumor, heart, kidney, liver, lungs and spleen) were removed 48 h post-transfection and homogenized in the lysis buffer. Luciferase activities in the lysates were measured as described above. For histological analysis of green fluorescent protein expression, the xenografted LS174 T tumors were dissected and immediately frozen. Six-micrometer cryosections were made using a LEICA CM 1510-cryostat (Wetzlar, Germany). The sections were examined by fluorescence microscopy.
In vivo anticancer therapy with anti-TAG-72 PILs encapsulating antiangiogenic genes Xenograft tumors were induced by subcutaneous injection of 2.5 Â 10 6 LS174 T cells into the back of 6-week-old female nude mice. A pDNA mixture (naked pDNA-A/E/ S) containing an equal amount of pFLAG-AngioK1/3 encoding angiostatin K1-K3 (A), pFLAG-Endo encoding endostatin (E) and pFLAG-Sax encoding saxatilin (S) was prepared. Mice bearing tumors (70-100 mm 3 ) were slowly injected with either the naked pDNA-A/E/S, empty pDNA-encapsulating anti-TAG-72 PILs (PILsempty) or pDNA-encapsulating anti-TAG-72 PILs-A/E/S through the tail vein (n ¼ 4). Every week from day 7 after inoculation, the mice were transfected with 50 mg of DNA in 0.3 ml saline per mouse and their tumor sizes were measured in two dimensions using calipers (volume ¼ width 2 Â length Â 0.52). For immunocytochemistry of tumor vascularization, tumor tissues were collected on day 28 after tumor inoculation and paraffin-embedded. Tumor sections (6 mm in thickness) were deparaffinized and then rehydrated. The tumor sections were stained with hematoxylin and then incubated in an enclosed container with 0.5 mg ml À1 of rabbit anti-von Willebrand factor antibody (Chemicon, Temecula, CA) for 2 h. The primary antibody was detected with a blood vessel staining kit (Chemicon). Because microvessels are distributed heterogeneously throughout the tumor, the sections were examined at a low magnification ( Â 10) to identify the areas of greatest vascularity (hot spots) according to the method of Weidner. 24 Within these areas, a minimum of 10 fields at Â 40 magnification were examined.
Statistical analysis
The statistical significance of the experimental results was analyzed by the Student's t-test. The difference between two mean values was considered as significant when the probability (P) was 0.05 or lower.
Results
Specificity of humanized antibody CC49 (HuCC49) to TAG-72
To examine the target specificity of HuCC49 IgG, TAG-72 expression in LS174 T colon adenocarcinoma cell lines was verified by western blotting analysis and immunofluorescence cell staining. Extracts of TAG-72-positive LS174 T and TAG-72-negative WiDr colon adenocarcinoma cells were prepared by cell lysis and the presence of TAG-72 protein (200-400 kDa) in the cell extracts was confirmed by western blot analysis using HuCC49 IgG as a primary antibody (Figure 1a) . In addition, TAG-72 expression on the LS174 T cell surface was visualized by immunofluorescence staining using the HuCC49 Fab 0 fragments and Fab 0 -specific FITC-labeled secondary antibody (Figure 1b) . The results of these experiments clearly showed that both the whole HuCC49 antibody and its Fab 0 fragments specifically target TAG-72.
Plasmid DNA encapsulation into PILs
The mean diameter of the PILs carrying pDNA in their interior was carefully controlled to approximately 100 nm through filtration. As determined by measurement of the number of lipid molecules per vesicle, there are approximately 3000 strands of PEG 2000 molecules attached to the liposome surface and about 1% of these PEG strands are conjugated with HuCC49 Fab 0 fragments. 13, 25 Nuclease treatment was able to remove any pDNA, either free or bound to the exterior of liposomes. Ethidium bromide staining after agarose gel electrophoresis demonstrated complete removal of any surface-bound pDNA from the preparation. To assess the role of PILs in protecting the encapsulated pDNA from attack by degradative enzymes in vivo, an in vitro DNase I protection assay was performed with PILs prepared with varied mole percentages of cationic lipid. Gel electrophoresis data showed that the pDNA encapsulated within the PILs was effectively protected from DNase I (Figure 2 ) and that free pDNA was completely degraded by DNase I treatment ( Figure 2 , lane 2-6). It also provided valuable information that the efficiency of pDNA encapsulation varied with the molar ratio of cationic lipid (DMKD) in the PILs. The amount of encapsulated pDNA was measured with a UV spectrometer after treatment of the PILs with Triton X-100. The pDNA encapsulation (Figures 3a and b) . Moreover, the cellular association of the anti-TAG-72 Fab 0 -PILs to TAG-72-positive LS174 T cells was completely blocked by addition of a 25-fold excess of free anti-TAG-72-Fab 0 fragments 30 min before treatment with the anti-TAG-72 Fab 0 -PILs (Figure 3c ). Inclusion of higher concentrations of DMKD cationic lipid in the immunoliposomes resulted in increased non-specific binding to WiDr cells.
Anti-TAG-72 PIL-mediated gene transfection of tumor cells in vitro
The in vitro transfection efficiency of anti-TAG-72 Fab 0 -PILs encapsulating pAAV-CMV-Luc encoding the firefly luciferase gene was evaluated in LS174 T and WiDr cells. Generally, for transfection to LS174 T cells, the anti-TAG-72 PILs were a more effective gene carrier than either DOTAP-based or DMKD-based conventional cationic liposomes. All of the prepared immunoliposomes exhibited effective transfection of LS174 T tumor cells and not WiDr cells at all, testifying to the TAG-72-mediated specific gene-transfer capability of these immunoliposomes ( Figure 4 ). Moreover, their specific gene transfection was effectively sustained even in the present of 60% serum. From the results obtained, the optimal ratio of DMKD cationic lipid for in vivo transfection was found to be 3-4 M percent.
Tumor-targeted systemic gene delivery by anti-TAG-72 PILs
To examine their tumor-specific gene-transfer capability, anti-TAG-72 Fab 0 PILs with varied DMKD cationic lipid ratios were prepared and injected intravenously into nude mice bearing LS174 T xenografts. As expected, at 48 h post-administration of the anti-TAG-72 PILs, the LS174 T tumor tissues displayed a higher level of luciferase expression than any other major organ. Among the prepared formulations, immunoliposomes containing 4 M percent DMKD were the most effective in transgene delivery into tumor tissues. By contrast, DMKD-based cationic lipoplexes exhibited the highest gene expression in the lungs ( Figure 5 ).
The tumor-specific transgene expression mediated by anti-TAG-72 PILs and conventional DMKD lipoplexes was also compared by monitoring the GFP expression. Frozen sections of LS174 T tumor tissues from the transfected nude mice were examined under a fluorescence microscope. The anti-TAG-72 PILs exhibited sufficient GFP expression in tumors to be viewed, while the DMKD lipoplexes did not ( Figure 6 ). The pattern of the GFP expression was similar to that of the luciferase expression ( Figure 5 ). Immunoliposomes containing 4 M percent DMKDs were the most effective in GFP expression in the tumors.
Systemic anticancer gene therapy using anti-TAG-72 PILs
We previously reported that in vivo transfection with the antiangiogenic genes angiostain K1/3, endostatin and saxatilin, was effective in inhibiting tumor growth and metastasis. 16, 17 The anticancer efficacy of anti-TAG-72 
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Fab 0 -PILs encapsulating these three genes was examined in nude mice bearing LS174 T xenograft tumors. Nude mice bearing tumors of 70-100 mm 3 were injected intravenously every 7 days with naked pDNA mixtures of pFALG-AngioK1/3, pFLAG-Endo and pFLAG-Sax, or with anti-TAG-72 Fab 0 -PILs encapsulating these three plasmids. Mice treated with the anti-TAG-72 Fab 0 -PILs encapsulating the three genes exhibited the most effective inhibition of tumor growth compared to untreated mice or those treated with naked pDNA or empty anti-TAG-72 PILs (Figures 7a and b) . Compared to the naked pDNA treatment, administration of the antiangiogenic genes encapsulated in anti-TAG-72 PILs showed an approximately 80% reduction in tumor growth, 28 days post-tumor inoculation.
After the last measurement of size, tumor tissues were removed from the mice, sectioned and then stained with hematoxylin and anti-von Willebrand factor antibody reactive to microvessels. The number of microvessles in the tumor tissues of the mice treated with the anti-TAG-72 PILs encapsulating the three antiangiogenic genes was significantly lower (microvessel density (MVD) mean ; 6.4 ± 0.7 mm À2 ) than those of the untreated mice (MVD mean ; 32.1 ± 1.7 mm À2 ), the mice treated with the naked pDNA (MVD mean ; 28.5±1.5 mm
À2
) or the PILsempty (MVD mean ; 26.9±1.3 mm À2 ) (Figure 7c ). These results implied that the inhibition of tumor growth was due to more efficient expression of the three antiangiogenic genes transferred by the anti-TAG-72 PILs.
Discussion
A variety of gene delivery systems, including viral and non-viral vectors, have been developed for gene therapy. Their infectivity makes viral vectors attractive as gene delivery systems. However, they also exhibit essential drawbacks such as immunogenicity, cytopathicity or recombinogenicity. 26 Generation of novel viruses with new targets for infection through genetic alteration also raises the theoretical possibility that these viruses can be transformed into new human pathogens. Consequently, a great deal of attention has been directed to non-viral vectors for the delivery of molecular therapeutics. 3, 4 The most extensively utilized non-viral vector is the lipoplex, a complex between cationic liposomes and pDNA. The liposome approach offers a number of advantages over viral vectors, such as less immunogenicity and no risk of evolution into new classes of infectious pathogens. In addition, liposomal vectors can easily accept targetspecific ligands for target-directed gene delivery.
The transfection efficiency of cationic liposomes can be increased dramatically when they bear ligands recognized by cell surface receptors. 4 It has been well documented that receptor-mediated endocytosis represents a highly efficient internalization pathway in eukaryotic cells. 27, 28 The presence of endocytic ligands on liposomes facilitates the entry of DNA into cells through the initial binding of these ligands to their receptors, followed by internalization of the bound complex. The enhanced gene transfection induced by transferrin coupled to liposomes is a typical example of ligand-mediated gene delivery. 29, 30 Specific antibodies can also be attached to liposomal surfaces, enabling them to be directed to selected tumorcell surface antigens. [31] [32] [33] It has been reported that anti-HER-2 monoclonal antibody Fab 0 fragments conjugated to liposomes bind specifically to breast cancer cell line SK-BR-3 overexpressing the HER-2/neu (EFG receptor), resulting in enhanced internalization of the liposomes. 14, 34 More recently, there have been a number of studies that utilized antibodies against tumor-associated antigens coupled to liposomes to target tumor cells for delivery of genes and drugs. 14, 20, [34] [35] [36] In this study, we conjugated Fab 0 fragments of humanized anti-TAG-72 antibodies (HuCC49) to liposomes encapsulating pDNA for tumor-directed gene delivery. The Fab 0 fragments retained the capability of specific binding to TAG-72 expressed on LS174 T tumor cells. The Fab 0 fragments were conjugated by means of disulfide linkage to PEG termini exposed on the liposomal surface. This type of linkage between the Fab 0 molecules and liposomes can have two meaningful advantages, effective outward exposition of the antigenbinding domain of the Fab 0 and enhanced half life of the immunoliposomes in the blood circulation. Regardless of the targeting ligand used, at least two fundamental requisites must be achieved for targeted liposomal systems to be therapeutically useful. First, administered targetdirected liposomes must have a reasonable plasma circulation times to allow access to a tumor site. It has already been shown that the blood circulation half life of the Fab 0 -coupled PILs is similar to that of long circulating PEG liposomes. [13] [14] [15] Second, ligand-conjugated liposomes that have accessed the tumor interstitium must have the potential to bind to defined target cells. The results of the in vitro binding assay of the Fab 0 PILs (Figure 3 ) verified that the anti-TAG-72 immunoliposomes were formulated for successful gene delivery directed to LS174 T cells.
Another major parameter governing tumor-directed gene transfection by immunoliposomes is effective pDNA encapsulation into liposomal vesicles. It is relatively easy for conventional cationic liposomes to be complexed to negatively charged pDNA by simple mixing. 37 The resulting lipoplexes, formed by a combination of electrostatic attraction and hydrophobic interactions, have a net positive charge that facilitates transfection of cells. 2, 3 However, the positively charged liposomal surface negatively affects liposome transit into target cells. Therefore, pDNA encapsulation in liposomal vesicles is a major concern in the preparation of electrically neutral (or negative) immunoliposomes. To enhance pDNA encapsulation, we have carefully and systematically formulated PILss by varying the liposome constituents and found that pDNA condensation by cationic lipid molecules effectively elevates the efficiency of pDNA encapsulation into liposomal vesicles. Varied amounts of DMKD cationic lipid (2-10 M percent) was added to POPC/ DSPE-based liposomes to prepare anti-TAG-72 Fab 0 -PILs that were then assayed through a gel retardation assay, a cell-binding assay and an in vitro/in vivo transfection assay. The highest pDNA encapsulation was provided by addition of 5 M percent DMKD. The best gene transfection was given by addition of 4 M percent DMKD. Presumably, up to 4-5 M percent, DMKD molecules may be mainly located in the inner leaflet of liposomal vesicles and effectively interact with electronegative pDNA molecules, resulting in the highest pDNA accommodation. At higher than 5 M percent, DMKD molecules may exist in the both leaflets of vesicles, interfering with effective pDNA encapsulation in liposomal vesicles. These findings emphasize the fact that besides the targeting ability of the selected antibody, liposome composition is critical and must be taken into account in the design of target-directed therapeutic complexes. Numerous studies have demonstrated that liposome formulations optimized for in vitro transfection may not be always the best for in vivo gene delivery 3, 4 because the microenvironment that liposomes encounter in vivo is very different from that experienced in vitro. 38 However, among the formulations prepared in this study, the anti-TAG-72 PIL formulation optimized for in vitro transfection exhibited the most efficient in vivo transfection.
Specific association of immunoliposomes with their target cells is a necessary requirement for target-specific gene delivery. The anti-TAG-72 Fab 0 -PILs were readily bound to LS174 T cells and their target cell-binding affinity was superior to that of undirected PEG-Mal liposomes. In addition, the intravenously administered anti-TAG-72 Fab 0 -PILs were able to deliver transgenes to xenografted tumor tissues overexpressing TAG-72 more efficiently than non-targetable conventional cationic liposomes. While the conventional cationic lipoplexes became deposited in pulmonary capillary beds because of their aggregation with serum proteins in blood circulation, 39 the PILs with electrically neutral surface were able to effectively pass through the lungs as well as avoid RES in the liver.
Using the optimized anti-TAG-72 Fab 0 -PIL formulation, we prepared LS174T-directed immunoliposomes encapsulating anticancer therapeutic genes. Previously, we postulated that co-expression of antiangiogenic genes having non-overlapping antiangiogenic mechanisms might be synergistically (or additively) more effective in inhibition of tumor progression. 16, 17 It was shown that the anticancer therapeutic genes, angiostain K1/3, endostatin and saxatilin, were effectively expressed after either subcutaneous or hydrodynamic administration, and that the resulting gene products were therapeutically accessible to the experimental tumor areas. 16, 17 In this study, antiangiogenic genes delivered with anti-TAG-72 Fab 0 -PILs also exhibited more significant inhibition of LS174 T tumor growth in vivo than the corresponding free pDNA or empty vector-encapsulating anti-TAG-72 Fab 0 -PILs. These results implied that tumor-directed delivery of genes could provide a more significant therapeutic effect than the other treatments.
In summary, a novel type of long-circulating immunoliposomes was designed for the in vivo gene therapy of colon cancers. The small uniform PILs were coupled to Fab 0 fragments of genetically engineered 'humanized' antibodies against TAG-72 antigens overexpressed in 
